Nicholas Cox is a Principal Scientist at Eli Lilly and Company since October 2025, bringing extensive experience in lipid nanoparticle (LNP) development for targeted delivery systems. Previously, Nicholas held positions at Verve Therapeutics as Scientist I and Associate Scientist, focusing on the creation of novel LNPs for hepatic and extra-hepatic delivery through innovative screening assays. At Intellia Therapeutics, Nicholas worked as a Senior Research Associate, formulating LNPs for hepatic delivery and investigating their mechanistic pathways. Nicholas also has experience as a Research Associate, where the formulation of LNPs for in vitro and in vivo studies was emphasized, and as a Characterization Intern at Amastan Technologies. Nicholas's educational background includes a Master's degree in Pharmaceutical Sciences, expected by 2026, and a Bachelor's degree in Chemistry with a focus on Organic Chemistry from the University of Massachusetts Lowell.
This person is not in the org chart
This person is not in any teams
This person is not in any offices